Lv11
38 积分 2021-10-27 加入
A note on quantifying follow-up in studies of failure time
1小时前
待确认
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era
2个月前
已完结
Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics
2个月前
已完结
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs
2个月前
已完结
A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials
2个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
2个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
3个月前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
5个月前
已完结
Emerging Strategies for the Treatment of Small Cell Lung Cancer
5个月前
已完结
Extensive‐stage small‐cell lung cancer: Current management and future directions
5个月前
已完结
皖公网安备34019202002308
